Recent News

• 01.27.2026 - Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
• 01.22.2026 - Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
• 12.29.2025 - Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026
• 12.22.2025 - Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
• 12.15.2025 - Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
• 12.08.2025 - Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
• 12.03.2025 - Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Recent Filings

• 01.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 8-K Current report
• 11.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 4 Statement of changes in beneficial ownership of securities